NASDAQ · Biotechnology

Nkarta, Inc. (NKTX) Stock

$1.79 +2.87% NASDAQ: NKTX Healthcare

Valuation

MetricValue
Price$1.79
Market Cap$128.21M
P/E Ratio-1.64
P/B Ratio0.77
P/S Ratio0.00
EPS (TTM)$-1.41
52-Week High$3.72
52-Week Low$1.70
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-39.64%
ROA-34.75%
ROCE-42.11%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.30
Current Ratio12.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-86.0M$-119.0M$-132.0M$-128.0M$-121.0M
Net Profit$-86.0M$-114.0M$-118.0M$-109.0M$-104.0M
EPS$-2.62$-2.61$-2.40$-1.60$-1.41
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$274.0M$473.0M$379.0M$501.0M$404.0M
Total Liabilities$23.0M$101.0M$106.0M$93.0M$92.0M
Cash$61.0M$37.0M$31.0M$28.0M$40.0M
Borrowings$12.0M$83.0M$88.0M$80.0M$76.0M

Latest News

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference GlobeNewswire · Jun 26, 2026 TD Cowen Initiates Nkarta at Buy MT Newswires · Jun 23, 2026 Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation Simply Wall St. · May 14, 2026 Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-57.0M$-86.0M$-100.0M$-89.0M
Investing Cash Flow$28.0M$-232.0M$51.0M$-134.0M$99.0M
Financing Cash Flow$0$2.0M$0$1.0M$0
Net Cash Flow$-34.0M$-23.0M$-6.0M$-3.0M$12.0M
Free Cash Flow$-73.0M$-104.0M$-114.0M$-104.0M$-90.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.18
EV / EBITDA-2.16
FCF Yield-50.97%
Quick Ratio7.98
Interest Coverage—
Return 1Y40.21%
Return 3Y33.17%
Return 5Y-91.16%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALECAlector, Inc. $1.83 +0.00% -1.74 $204.33M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
ELTXElicio Therapeutics, Inc. $1.90 -2.06% -0.89 $36.23M 0.00%
FATEFate Therapeutics, Inc. $2.11 +0.96% -2.21 $245.94M 0.00%

About Nkarta, Inc.

Nkarta, Inc. is led by CEO Paul J. Hastings, publicly traded since 2020.

Nkarta, Inc. (NKTX) stock trades at $1.79 with a market capitalization of $128.21M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.64, reflecting a net loss over the last twelve months, price-to-book of 0.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.70 and $3.72, and currently trades 51.9% below its 52-week high.

On profitability, Nkarta, Inc. generates a return on equity (ROE) of -39.64% (negative, reflecting a net loss), return on capital employed of -42.11%.

Nkarta, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Nkarta, Inc. reported revenue of $7.0M rising to $0, a change of -100.0% across 8 years. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-104.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-117.0M.

Borrowings rose from $13.0M to $76.0M, cash from operations was $-89.0M in the latest year, positive in 0 of the last 8.

Return on equity has averaged -33.6% over five years, and was -33.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Nkarta, Inc. (NKTX) — frequently asked questions

What is Nkarta, Inc. (NKTX) stock price today?

Nkarta, Inc. (NKTX) is currently trading at $1.79, up 2.87% today.

What is NKTX P/E ratio?

Nkarta, Inc.'s P/E ratio is -1.64. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is NKTX return on equity (ROE)?

Nkarta, Inc.'s return on equity (ROE) is -39.64%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Nkarta, Inc.'s market cap?

Nkarta, Inc. has a market capitalization of $128.21M.

Does NKTX pay a dividend?

Nkarta, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does NKTX carry?

Nkarta, Inc. has a debt-to-equity ratio of 0.30. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is NKTX's profit margin?

Nkarta, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is NKTX in?

Nkarta, Inc. is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is NKTX listed on?

Nkarta, Inc. trades on NASDAQ under the ticker NKTX.

What is NKTX's 52-week range?

Over the last year Nkarta, Inc. has traded between $1.70 and $3.72.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens NKTX currently matches

On the figures above, Nkarta, Inc. passes the filters for 3 of our ready-made screens, among them Penny Stocks, Stocks Under $5, Micro Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Penny StocksStocks Under $5Micro Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.